Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerShanu Modi, David Cameron, Junji Tsurutani et al.|New England Journal of Medicine|2022Cited by 2.5k
A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer.Zefei Jiang, Hua Yang, Tao Sun et al.|Journal of Clinical Oncology|2022Cited by 36
Matrine suppresses breast cancer metastasis by targeting ITGB1 and inhibiting epithelial‑to‑mesenchymal transitionLili Ren, Xiaojia Wang|Experimental and Therapeutic Medicine|2019Cited by 27